Hudson Bay Capital Management’s Biocept, Inc. BIOC Stock Holding History

Hudson Bay Capital Management’s Portfolio BIOC Stock Details BIOC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-123	Closed	-$26K	–	661
2020 Q2	$26K	Buy	+123	New	+$17.6K	﹤0.01%	482
2017 Q2	–	Sell	-44	Closed	-$851K	–	855
2017 Q1	$851K	Buy	+44	New	+$748K	0.01%	646

Other funds holding BIOC

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

HSA

Hussman Strategic Advisors Ellicott City, Maryland $434M AUM 19.64% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Creative Planning Overland Park, Kansas $147B AUM 18.73% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Hudson Bay Capital Management's BIOC Position: Q3 2020 in Review

Hudson Bay Capital Management sold out of Biocept, Inc. (BIOC) in Q3 2020, closing a stake of 123 shares — an estimated $26K sold.

Hudson Bay Capital Management first reported a position in BIOC in Q1 2017 and held it in 2 quarters. The position peaked at $851K in Q1 2017. 18 funds tracked by Wall St. Rank hold BIOC as of Q3 2020.

Hudson Bay Capital Management reported no remaining Biocept, Inc. position as of Q3 2020 after selling out during the quarter.
Hudson Bay Capital Management sold 123 Biocept, Inc. shares in Q3 2020, an estimated $26K.
Hudson Bay Capital Management first reported a position in Biocept, Inc. in Q1 2017 and held it in 2 quarters.
Hudson Bay Capital Management's Biocept, Inc. position peaked at $851K in Q1 2017.
18 funds tracked by Wall St. Rank held Biocept, Inc. as of Q3 2020.

Based on Hudson Bay Capital Management's 13F filing for Q3 2020, filed 12 Nov 2020.